Intuitive Surgical Q4 2025 Earnings Analysis

# Beta Finch Podcast Script: Intuitive Surgical Q4 2025 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're unpacking Intuitive Surgical's Q4 2025 results - and folks, this robotics giant just delivered some seriously impressive numbers.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And wow, where do we even start with these results? Intuitive absolutely crushed it this quarter. We're talking about a company that just crossed the 20 million patient milestone since 1997 and shows no signs of slowing down.**ALEX:** Let's hit the headline numbers first. Revenue grew 21% to hit $10.1 billion for the full year - that's massive growth for a company this size. And quarterly revenue was up 19% to $2.87 billion. But Jordan, what really caught my eye was the procedure growth.**JORDAN:** Absolutely. Total procedures grew 19% for the year to over 3.1 million. That's not just impressive - it's accelerating adoption of robotic surgery worldwide. Da Vinci procedures specifically were up 18%, with their single-port procedures exploding 87% year-over-year. That tells me surgeons are really embracing these newer technologies.**ALEX:** And geographically, the story gets even better. US procedures grew 15%, but international was the real star - up 23% with particularly strong performance in Europe at 21%, Asia at 24%, and rest of world markets at 27%. It's becoming a truly global story.**JORDAN:** What I found fascinating was the capital equipment side. They placed 1,721 da Vinci systems in 2025, including 870 of their newest da Vinci 5 systems. The demand for upgrades is clearly there, especially with the dual console systems for training and mentoring. That speaks to hospitals really investing in their robotic surgery capabilities long-term.**ALEX:** Let's talk margins for a second. Operating margins came in at 37%, which is solid, though they're dealing with some headwinds. CEO David Rosa mentioned tariffs are hitting them for about 95 basis points, plus they're investing heavily in R&D and scaling manufacturing. But they're managing it well with cost efficiency initiatives.**JORDAN:** The tariff impact is significant - they're forecasting 120 basis points of impact in 2026, up from about 65 basis points in 2025. That's a real cost pressure they're navigating. But here's what's interesting - they're still guiding for gross margins of 67-68% in 2026, essentially flat despite these headwinds.**ALEX:** Now, one of the most exciting developments from this call was the FDA clearance for cardiac procedures on the da Vinci 5. Jordan, this could be huge, right?**JORDAN:** Potentially massive, Alex. They performed about 17,000 cardiac procedures globally in 2025, which sounds small, but Rosa mentioned the addressable market for da Vinci 5 in just the US and Korea is around 160,000 procedures annually. Cardiac surgery is complex, high-value work, so even modest penetration could move the needle significantly.**ALEX:** The Q&A session revealed some really interesting strategic directions. They're making a big push into ambulatory surgery centers - ASCs. Rosa explained they're targeting higher-volume ASCs, particularly those affiliated with existing hospital customers where surgeons are already da Vinci trained.**JORDAN:** That ASC strategy is smart. About 70% of the ASC opportunity is with their existing IDN customers, so they have built-in relationships and trained surgeons. They're using their refurbished XI systems - the "XIR" - as the entry point, which gives them a lower-cost option for price-sensitive ASC market.**ALEThis episode includes AI-generated content.